Phast develops sustainable, high-performance polyhydroxyalkanoate (PHA) biopolymers intended for medical applications. The company plans to expand R&D, grow its team, advance product development, and accelerate commercialisation of its next-generation PHA-based medical products. To support those efforts, Phast secured a £1 million pre-seed funding package combining £500,000 in equity from an angel round led by Sheffield Angels with participation from Cambridge Angels and Mandashi, matched by a £500,000 Innovate UK Investor Partnership Grant. The funding increases the company’s runway for development and early commercial activities. Phast is headquartered in Sheffield. The article did not disclose revenue, users, or prior financing history.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2026